Focus on IL-6 Inhibitors for Optimizing Multimodal Management of RA
A Real World Approach to Unmet Needs, Patient-Centric Care, Special Populations, and Sequencing Biologic Therapies for Rheumatoid Arthritis (RA)
A Real World Approach to Unmet Needs, Patient-Centric Care, Special Populations, and Sequencing Biologic Therapies for Rheumatoid Arthritis (RA)
Course Videos
Video
What is the precise immunopathobiologic mechanism of action for agents targeting IL-6 in the setting of RA? Are these MoAs synergistic with other MoAs? If so with which other agents should IL-6 targeting agents be used?
Video
What are accepted treatment triggers for employing disease-modifying anti-rheumatic drugs (DMARDs)? And what classes of biologic agents — including IL-6 inhibitors and others — have demonstrated efficacy as monotherapy?
Video
What new data related to the use of TNFIs and the use of IL-6 inhibitors do we have as it relates to drug persistence and safety profiles?
Video
How does the IL-6 pathway and family of cytokines affect inflammation and non-joint clinical manifestations?
Video
What biomarkers, clinical findings, or previous treatment history do you rely on to identify patients who might be uniquely responsive to IL-6 inhibition?
Video
Can you discuss the unique mechanistic effects of IL-6 inhibition — including the role of GP 130 — that differentiate it from other cytokines that are targeted in RA? Can its signaling properties be transmitted to sites distal from inflammation?
Video
Is there a systematic approach for aligning specific cohorts of patients with RA with specific therapies? With IL-6 inhibitors, TNFIs, or co-modulating activating agents?
Video
What disease activity measures for RA do you consider to be most important?
What disease activity measures for RA do you consider to be most important?
Video
Can you compare the translational implications of inhibiting the TNF vs IL-6 cytokine signaling systems? How are these differences manifested clinically?
Video
When are combination approaches — with a DMARD and biologic — used to treat RA and when might monotherapeutic approaches be preferable?
Video
What percentage of patients started on a TNFI will respond and to what degree will they respond?
What percentage of patients started on a TNFI will respond and to what degree will they respond?
